Targeting piRNA‐137463 Inhibits Tumor Progression and Boosts Sensitivity to Immune Checkpoint Blockade via De Novo Cholesterol Biosynthesis in Lung Adenocarcinoma
Advanced Science · 2025
DOI: 10.1002/advs.202414100 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Yuning Zhan und 10 weiteren Autor:innen. Beteiligte Einrichtung: The Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, 150 Haping Road, Harbin, 150081, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Cholesterol, Adenocarcinoma of Lung, RNA, Small Interfering. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Funding of Heilongjiang, Haiyan Foundation of Harbin Medical University Cancer Hospital.
Abstract (Originalsprache)
The important role of PIWI‐interacting RNAs (piRNAs) in tumors has garnered increasing attention. However, research on their role in lung adenocarcinoma (LUAD) remains limited. Elevated levels of piRNA‐137463 have been linked to poor prognosis in LUAD patients. Inhibition of piRNA‐137463 curbed the proliferation, migration, and invasion of LUAD cells, enhanced T cell cytotoxicity through increased IFN‐γ secretion, disrupted cholesterol metabolism, and reduced intracellular cholesterol, lipid raft content, and PD‐L1 expression in LUAD cells. Bioinformatic prediction identified a potential interaction between piRNA‐137463 and lncRNA LOC100128494. Inhibiting piRNA‐137463 increased the stability and expression of LOC100128494, which further modulated insulin‐induced gene 1 protein (INSIG1) levels via a competitive endogenous RNA network involving LOC100128494 and miR‐24‐3p. Notably, the effect of piRNA‐137463 in LUAD cells is dependent on the expression of LOC100128494 and INSIG1. Inhibiting the expression of piRNA‐137463 with AntagopiRNA‐137463 suppressed tumor growth and metastasis via LOC100128494 in nude mice and enhanced the response of LUAD to anti‐PD‐1 therapy in immune‐competent mice. In summary, this study elucidates the role of piRNA‐137463 in the reprogramming of cholesterol metabolism, which drives the progression of LUAD, thereby identifying a new target for the comprehensive clinical management of LUAD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, 150 Haping Road, Harbin, 150081, China.
- NHC and CAMS Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University, Harbin, 150001, China.
- Imaging Center, Harbin Medical University Cancer Hospital, Harbin, 150081, China.
- The Department of Orthopedics, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150001, China.
ORCID-Profile: Yuning Zhan, Li Cai, Ying Xing
Förderung
- National Natural Science Foundation of China
- Natural Science Funding of Heilongjiang
- Haiyan Foundation of Harbin Medical University Cancer Hospital
- Top-Notch Youth Fund from Harbin Medical University Cancer Hospital
Zitieren
APA
Zhan, Y., Tian, F., Fan, W., Li, X., Wang, X., Zhang, H., Hong, X., Wang, X., Cai, L., Song, Y., & Xing, Y. (2025). Targeting piRNA‐137463 Inhibits Tumor Progression and Boosts Sensitivity to Immune Checkpoint Blockade via De Novo Cholesterol Biosynthesis in Lung Adenocarcinoma. Advanced Science. https://doi.org/10.1002/advs.202414100
Vancouver
Zhan Y, Tian F, Fan W, Li X, Wang X, Zhang H, et al. Targeting piRNA‐137463 Inhibits Tumor Progression and Boosts Sensitivity to Immune Checkpoint Blockade via De Novo Cholesterol Biosynthesis in Lung Adenocarcinoma. Advanced Science. 2025. doi:10.1002/advs.202414100
BibTeX
@article{Zhan2025,
author = {Zhan, Yuning and Tian, Fanglin and Fan, Weina and Li, Xin and Wang, Xiangyu and Zhang, Hongxia and Hong, Xin and Wang, Xin and Cai, Li and Song, Yang and Xing, Ying},
title = {Targeting piRNA‐137463 Inhibits Tumor Progression and Boosts Sensitivity to Immune Checkpoint Blockade via De Novo Cholesterol Biosynthesis in Lung Adenocarcinoma},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202414100}
}
EUVIMED